Enveric Biosciences Advances Lead Candidate EB-003 Towards Clinical Trials with Successful Pre-IND Study Completion

Enveric Biosciences Inc., a biotechnology company specializing in the development of novel neuroplastogenic small-molecule therapeutics, has successfully completed pre-IND Dose Range Finding (DRF) toxicology studies for its leading drug candidate, EB-003. The studies, conducted in two preclinical species, have established the Maximum Tolerated Dose $(MTD)$ of EB-003, which targets neuropsychiatric indications such as depression and post-traumatic stress disorder (PTSD). The results, which confirmed oral bioavailability and brain penetration, were noted for dose-dependent increases in plasma concentrations and CNS-related effects, suggesting potential on-target activity. These findings are pivotal for advancing EB-003 towards IND-enabling studies and First-in-Human clinical trials. Enveric plans to proceed with definitive toxicology, safety pharmacology, and genotoxicity studies to support an IND submission to the FDA. No specific future presentation of these results has been announced.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250828631258) on August 28, 2025, and is solely responsible for the information contained therein.